EUS-guided fine-needle injection for pancreatic cancer: back to the future
In this issue of Gastrointestinal Endoscopy, Lee et al1 report a phase I trial of EUS-guided fine-needle injection (EUS-FNI) of modified adenovirus with “double suicide” genes, a second-generation oncolytic virus, for locally advanced pancreatic cancer. The treatment was safe without dose-limiting toxicity during the first 8 weeks; partial resp onse was seen in 1 patient, and the disease was stable in the remaining 8 patients at 12 weeks.
Source: Gastrointestinal Endoscopy - Category: Gastroenterology Authors: Yousuke Nakai, Kenneth J. Chang Tags: Original article Source Type: research
More News: Adenoviruses | Cancer | Cancer & Oncology | Endoscopy | Gastroenterology | Genetics | Pancreas | Pancreatic Cancer | Toxicology